NervGen Pharma Corp.
NGENF
$4.41
$0.184.26%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.94% | -14.70% | -25.71% | -6.38% | -21.81% |
| Total Depreciation and Amortization | -47.52% | -56.05% | -61.25% | -42.88% | -25.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.81% | -17.53% | -24.59% | -43.68% | 26.63% |
| Change in Net Operating Assets | 296.65% | 42.66% | 2.52% | 440.93% | -21.65% |
| Cash from Operations | -0.37% | -40.39% | -76.45% | -47.14% | -21.80% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 193.09% | 176.03% | 159.49% | 142.09% | 124.31% |
| Cash from Investing | 193.09% | 174.46% | 157.12% | 141.16% | 123.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -66.44% | -69.52% | -89.41% | 2,716.70% | 2,316.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 57.96% | 62.90% | 69.58% | -- | -1,163.80% |
| Cash from Financing | -68.38% | -71.28% | -91.64% | 2,861.01% | 2,812.73% |
| Foreign Exchange rate Adjustments | -5,020.45% | -234.26% | 26.98% | -139.54% | 97.89% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -245.63% | -199.91% | -225.28% | 154.49% | 149.46% |